A MULTICENTER RANDOMIZED STUDY IN RHEUMATOID ARTHRITIS TO COMPARE IGURATIMOD, METHOTREXATE, OR COMBINATION: 52 WEEK EFFICACY AND SAFETY RESULTS OF THE SMILE TRIAL
机构:[1]Renji Hospital of Shanghai Jiao Tong University School of Medicine, Department of Rheumatology, Shanghai, China[2]The First Affiliated Hospital of Anhui Medical University, Department of Rheumatology and Immunology, Hefei, China[3]The First Affiliated Hospital of USTC, Department of Rheumatology and Immunology, Hefei, China[4]Peking University People’s Hospital, Department of Rheumatology and Immunology, Beijing, China[5]Qilu Hospital of Shandong University, Department of Rheumatology, Jinan, China[6]Xiangya Hospital Central South University, Department of Rheumatology and Immunology, Changsha, China[7]China- Japan Union Hospital of JiLin University, Department of Rheumatology and Immunology, Changchun, China吉林大学中日联谊医院[8]Changhai Hospital of Shanghai, Department of Rheumatology and Immunology, Shanghai, China[9]First Affiliated Hospital, Nanjing Medical University, Department of Rheumatology and Immunology, Nanjing, China江苏省人民医院[10]The Second Affiliated Hospital Zhejiang University School of Medicine, Department of Rheumatology and Immunology, Hangzhou, China[11]ShangHai GuangHua Hospital of Integrated Traditional Chinese and Western Medicine, Department of Rheumatology, Shanghai, China[12]Xijing Hospital, Fourth Military Medical University, Department of Clinical Immunology, Xi’an, China[13]First Affiliated Hospital, Bengbu Medical College, Department of Rheumatology and Immunology, Bengbu, China[14]The Second Affiliated Hospital, Harbin Medical University, Department of Rheumatology and Immunology, Harbin, China[15]First Affiliated Hospital of Kunming Medical University, Department of Rheumatology and Immunology, Kunming, China内科科室风湿免疫科昆明医科大学附属第一医院[16]The Second Affiliated Hospital of Guangzhou Medical University, Department of Rheumatology and Immunology, Guangzhou, China[17]Jining No.1 People’s Hospital, Department of Rheumatology and Immunology, Jining, China[18]The Second Xiangya Hospital of Central South University, Department of Rheumatology and Immunology, Changsha, China[19]The Third Xiangya Hospital of Central South University, Department of Nephropathy and Rheumatology, Changsha, China[20]Zhuzhou Central Hospital, Department of Rheumatology and Immunology, Zhuzhou, China[21]Fudan University Zhongshan Hospital, Department of Rheumatology and Immunology, Shanghai, China[22]The First Affiliated Hospital of Shantou University Medical College, Department of Rheumatology, Shantou, China[23]The First Affiliated Hospital of Soochow University, Department of Rheumatology, Suzhou, China[24]West China Hospital, Department of Rheumatology and Immunology, Chengdu, China四川大学华西医院[25]Tianjin Medical University General Hospital, Department of Rheumatology and Immunology, Tianjin, China[26]China-Japan Friendship Hospital, Department of Rheumatology and Immunology, Beijing, China[27]Tongji Hospital Tongji Medical College of HUST, Department of Rheumatology and Immunology, Wuhan, China华中科技大学同济医学院附属同济医院[28]The First Hospital of China Medical University, Department of Rheumatology and Immunology, Shenyang, China
第一作者机构:[1]Renji Hospital of Shanghai Jiao Tong University School of Medicine, Department of Rheumatology, Shanghai, China
推荐引用方式(GB/T 7714):
F. Du,J. Xu,X. Li,et al.A MULTICENTER RANDOMIZED STUDY IN RHEUMATOID ARTHRITIS TO COMPARE IGURATIMOD, METHOTREXATE, OR COMBINATION: 52 WEEK EFFICACY AND SAFETY RESULTS OF THE SMILE TRIAL[J].ANNALS OF THE RHEUMATIC DISEASES.2021,80:574-575.doi:10.1136/annrheumdis-2021-eular.1486.
APA:
F. Du,J. Xu,X. Li,Z. Li,X. Li...&C. Bao.(2021).A MULTICENTER RANDOMIZED STUDY IN RHEUMATOID ARTHRITIS TO COMPARE IGURATIMOD, METHOTREXATE, OR COMBINATION: 52 WEEK EFFICACY AND SAFETY RESULTS OF THE SMILE TRIAL.ANNALS OF THE RHEUMATIC DISEASES,80,
MLA:
F. Du,et al."A MULTICENTER RANDOMIZED STUDY IN RHEUMATOID ARTHRITIS TO COMPARE IGURATIMOD, METHOTREXATE, OR COMBINATION: 52 WEEK EFFICACY AND SAFETY RESULTS OF THE SMILE TRIAL".ANNALS OF THE RHEUMATIC DISEASES 80.(2021):574-575